NCT07203742 The Effect of Mandala on Anxiety and Fear Levels in Children With Leukemia Before Intrathecal Chemotherapy Treatment
| NCT ID | NCT07203742 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ege University |
| Condition | Acute Lymphoblastic Leukemia |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-09-29 |
| Primary Completion | 2026-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-09-29 with a primary completion date of 2026-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to examine the effect of mandala coloring activity, administered before intrathecal chemotherapy treatment in children with leukemia, on pre-procedure anxiety and fear in children. The main question this study aims to answer is: Does mandala coloring administered before intrathecal chemotherapy treatment reduce pre-procedure anxiety and fear in children with leukemia? Descriptive demographic data will be collected from the children who will be given mandalas. Data will be collected using an Anxiety Scale and a Fear Scale.
Eligibility Criteria
Inclusion Criteria: * The patient must be between 4 and 12 years of age. * The patient must be hospitalized and followed up at the Pediatric Hematology Clinic. * The patient must only be receiving leukemia treatment. * The patient must not have any other chronic diseases. * The patient must not have any systemic infections. * The patient has received at least two courses of intrathecal chemotherapy treatment * The patient does not have a diagnosis of psychological/mental symptoms as a side effect of chemotherapy treatment * Intrathecal treatment will be administered to the patient in accordance with the chemotherapy protocol * The patient and the caregiver parent are volunteers * The caregiver parent speaks Turkish and is open to communication. Exclusion Criteria: * Cases that do not meet the inclusion criteria will be excluded from the study.
Contact & Investigator
Seda Ardahan Sevgili, Ph.D.
PRINCIPAL INVESTIGATOR
Ege University
Frequently Asked Questions
Who can join the NCT07203742 clinical trial?
This trial is open to participants of all sexes, aged 4 Years or older, up to 12 Years, studying Acute Lymphoblastic Leukemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07203742 currently recruiting?
Yes, NCT07203742 is actively recruiting participants. Contact the research team at sedardahan@gmail.com for enrollment information.
Where is the NCT07203742 trial being conducted?
This trial is being conducted at Izmir, Turkey (Türkiye).
Who is sponsoring the NCT07203742 clinical trial?
NCT07203742 is sponsored by Ege University. The principal investigator is Seda Ardahan Sevgili, Ph.D. at Ege University. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.